Silence Therapeutics Locks In $175M Upsized Offering with Underwriting Agreement

summarizeSummary

Silence Therapeutics formalized its upsized $175 million underwritten public offering, selling 12.96 million ADSs at $13.50 each with net proceeds of approximately $164 million.

check_boxKey Events · Financing and Capital Events · SLN

• Underwriting Agreement Executed

  An underwriting agreement was entered into with Jefferies LLC and Morgan Stanley & Co. LLC as representatives, along with Cantor Fitzgerald & Co and William Blair & Company, L.L.C., to sell 12,962,963 ADSs at a public offering price of $13.50 per ADS.

• Net Proceeds Estimated at $164M

  Net proceeds are estimated at approximately $164.0 million after underwriting discounts and expenses, or $188.7 million if the underwriters' 30-day option to purchase up to 1,944,444 additional ADSs is fully exercised.

• Offering Priced at $13.50 Per ADS

  The public offering price of $13.50 per ADS represents an 8.3% discount to the current stock price of $13.95, with underwriters purchasing at $12.69 per ADS.

• Closing Expected August 13, 2026

  The offering is expected to close on August 13, 2026, subject to customary closing conditions, providing immediate capital to fund the company's development programs.

auto_awesomeAnalysis · SLN · Life Sciences

The underwriting agreement for the upsized $175 million public offering has been executed, locking in final terms. Under the deal, 12,962,963 ADSs will be sold at $13.50 per share, with underwriters purchasing at $12.69 per ADS. Net proceeds are estimated at $164 million, or $188.7 million if the 30-day option for 1,944,444 additional ADSs is fully exercised. This capital raise follows the positive Phase 2 SANRECO data for divesiran and significantly extends the company's cash runway. While dilutive to existing shareholders, the offering provides substantial funding for continued development.